Searched for
FORTAMET
India will be world power in pharma, says Jhunjhunwala; is it time to buy?Jhunjhunwala continues to bet on the pharma sector and Aurobindo Pharma is his preferred pick, which has rallied a little over 6 per cent i...31 Aug, 2016, 10.29 AM IST- Growth will come on the back Gavis consolidation: Ramesh Swaminathan, CFO, Lupin"This year Gavis will actually add tremendously to the growth. We also have other molecules to launch after Glumetza and Fortament gets pha...25 Aug, 2016, 01.33 PM IST
- Lupin looks to launch 25 products in US this fiscalIn the current year, apart from the Gavis portfolio, Fortamet and Glumetza, the company expects to launch products like Minastrin and Epzic...15 Aug, 2016, 11.35 AM IST
- Credit Suisse downgrades Lupin to 'underperform'Credit Suisse has cut its FY18 EPS estimate for Lupin by 16%. Subsequently, the brokerage has lowered the target price to Rs 1,450 from Rs ...04 Aug, 2016, 12.06 PM IST
- Lupin nosedives 8% even as drugmaker reports 47% PAT growth in Q4The company had reported PAT of Rs 547 crore in the same quarter last financial year.20 May, 2016, 04.46 PM IST
- More USFDA nods to sustain Lupin’s good runThe stock closed 0.6% higher for the day following a higher-than-expected performance even as the BSE Healthcare index closed 0.5% lower an...20 May, 2016, 02.27 AM IST
- Headwinds for pharma pack ahead; 5 stocks top brokerages are positive onThe S&P BSE healthcare index plunged nearly 16% so far in 2016. Regulatory hurdles, expensive valuations and USFDA concerns capped upside f...21 Mar, 2016, 10.18 AM IST
- Difficult for Nifty50 to retest 7,000; 5 top stock recos from global brokeragesS&P BSE Sensex and Nifty50 have lost momentum after rallying over 6 per cent in the week gone by, but analysts advise investors that there ...10 Mar, 2016, 01.07 PM IST
- Lupin, Sobha, Escorts among top five stock ideas from brokeragesStock-specific movements are going to continue as companies that have delivered good numbers are good to be rewarded, possibly more than wh...08 Feb, 2016, 12.54 PM IST
- Lupin looks fairly valued, could rise another 4-5%: Mayuresh JoshiThe company is likely to see a decent topline growth of 17-18 per cent over the next two years., says Joshi.01 Oct, 2015, 04.20 PM IST
- US, Indian markets main drivers of growth in Q4: Nilesh Gupta, LupinIn the US, there are some products like Ziprasidone, Fortamet and products that we introduced like Tricor have been doing very well for the...08 May, 2013, 04.42 PM IST
- Will be interested in buying brands in US: S Ramesh, Lupin"Our current cash holdings are close to about $100-120 million and if you look at our debt-equity ratio, it is currently about 0.2. "18 Mar, 2013, 01.53 PM IST
- Lupin resumes anti-diabetic drug sales in US after court nodIn December last year, Shionogi's request for a preliminary injunction had been granted and had blocked Lupin from further sales of the pro...19 Apr, 2012, 01.29 PM IST
- US court restrains Lupin from selling generic drug 'Fortamet'The US court, however, denied the motion of Shionogi for recall of Lupin's already distributed generic Fortamet during the two weeks of at-...08 Dec, 2011, 09.57 PM IST
- Lupin launches Generic Diabetes drugIndian pharmaceutical major Lupin launched the generic version of Watson’s Fortamet despite an impeding patent suit against Lupin in the US.14 Oct, 2011, 05.33 AM IST
- Looking at acquisitions in Latin Ameican market: S Ramesh, Lupin Ltd.S Ramesh, President Finance and Planning, Lupin Ltd. in an interview with ET Now talks about the expected growth from the US market and the...15 Jun, 2011, 04.24 PM IST
- Lupin gets USFDA approval for diabetes drugThe company's US arm Lupin Pharmaceuticals Inc has received approval from the USFDA for Metformin Hydrochloride extended-release tablets.20 Apr, 2011, 02.41 PM IST
Load More
